Chinese Journal of Integrative Medicine

, Volume 24, Issue 3, pp 171–177 | Cite as

Efficacy and Safety of Quxie Capsule (祛邪胶囊) in Metastatic Colorectal Cancer: A Double-Blind Randomized Placebo Controlled Trial

  • Tong Zhang
  • Yu-fei Yang
  • Bin He
  • Dan-hui Yi
  • Jie Hao
  • Da Zhang
Original Article



To verify the efficacy and safety of Quxie Capsule (祛邪胶囊) in patients with metastatic colorectal cancer (mCRC).


The present study was a randomized, double-blind, placebo-controlled trial. Sixty patients with mCRC were randomized into two groups at a 1:1 ratio by sealed envelope. The treatment group received conventional therapy combined with Quxie Capsule for 3 months. The control group was treated with conventional therapy combined with placebo for 3 months. Main outcome measures were overall survival (OS) and progression-free survival (PFS). Subgroup analysis was performed according to age, right or left-sided disease, and second-line therapy to determine the differences in PFS and OS between the two groups. Patients were followed up every 3 months until Dec 31st 2016.


The median OS was 23 months in the treatment group [95% confidence interval (CI): 15–not calculated] vs. 14 months in the control group (95% CI: 11–22, P=0.060). The OS of the treatment group tended to be longer than that of the control group (P>0.05). In the subgroups of patients <65 years old, left-sided colon, and 2nd-line therapy, the treatment group showed a significant survival benefit compared with the control group (P=0.006, 0.038, 0.013, respectively). There were no significant differences between the two groups in PFS (P>0.05). Safety analysis showed no severe hematological toxicity or liver and renal function injury in the treatment group.


Quxie Capsule showed good safety and efficacy, and could prolong the OS of patients with mCRC. (Registration No. ChiCTR-IOR-16009733)


Chinese medicine Quxie Capsule metastatic colorectal cancer randomized controlled trial 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rebecca L, Siegel MPH, Kimberly D, Miller MPH, Ahmedin J, DVM PHD. Global cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.CrossRefGoogle Scholar
  2. 2.
    Chen WQ, Zheng RS, Zeng HM, Zhang SW, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res (Chin) 2015;27:2–12.CrossRefGoogle Scholar
  3. 3.
    Lin FX, Tian LF, Lei CY, Ding CC, Shi L, Zhang SF. Chinese medicine for outcomes in colorectal cancer patients: a retrospective clinical study. Chin J Integr Med 2017;23:648–653.CrossRefPubMedGoogle Scholar
  4. 4.
    Guo Y, Zou Y, Xu YF, Wang H, Li Y, Qian LY, Yang WH. Study on Chinese medicine syndrome of colorectal carcinoma in perioperative period. Chin J Integr Med 2015;21:183–187.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang YF, Xu Y, Wu Y, Wang LP, Li Z, Zhang LZ, et al. Randomized controlled clinical study of Quxie Capsule in reducing postoperative relapse and metastasis of colorectal cancer. Chin J Integr Tradit Chin West Med (Chin) 2007;27:879–882.Google Scholar
  6. 6.
    Yang YF, Chen ZX, Xu Y, Wu Y, Wu XW, Zhu YW, et al. Randomized controlled study of Quxie Capsule in improving survival and quality of life of advanced colorectal cancer patients. Chin J Integr Tradit Chin West Med (Chin) 2008;28:111–113.Google Scholar
  7. 7.
    Castleberry AW, Güller U, Tarantino I, Berry MF, Brugger L, Warschkow R, et al. Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. J Gastrointest Surg 2014;18:1194–1204.CrossRefPubMedGoogle Scholar
  8. 8.
    Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res J 2009;15:6391–6397.CrossRefGoogle Scholar
  9. 9.
    Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2016;2016:3797.Google Scholar
  10. 10.
    Thuong PT, Khoi NM, Ohta S, Shiota S, Kanta H, Takeuchi K. Ent-kaurane diterpenoids from Croton tonkinensis induce apoptosis in colorectal cancer cells through the phosphorylation of JNK mediated by reactive oxygen species and dual-specificity JNK kinase MKK4. Anticancer Agents Med Chem J 2014;14:1051–1061.CrossRefGoogle Scholar
  11. 11.
    Monica M, Riccardo B, Zheng C, Jenny B, Laura C, Guglielmina F. Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines. J Ethnopharmacol 2012;144:747–753.CrossRefGoogle Scholar
  12. 12.
    Li JL, Han SL, Fan X, Wang X, Zhang C, Liang HP, et al. Effects of evodiamine on autophagy of human colon cancer cells. Chin J Gener Surg (Chin) 2011;26:41–44.Google Scholar
  13. 13.
    Wang YH, Zhou ZH. The regulation effect of evodiamine on the malignant biological behavior of human colon cancer cell line HT29 and Wnt/ß-catenin signaling pathway. J Hainan Med Univ (Chin) 2016;8:729–731.Google Scholar
  14. 14.
    Ding N, Yang YF, Liu YN, Xu Y, He B. Study on the inhibitory effects and mechanism of Qingxue Granules and Quxie Capsule on proliferation of human colorectal cancer HCT-116 cell. China J Basic Med Tradit Chin Med (Chin) 2013;19: 38–40.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2017

Authors and Affiliations

  • Tong Zhang
    • 1
  • Yu-fei Yang
    • 1
  • Bin He
    • 1
  • Dan-hui Yi
    • 2
  • Jie Hao
    • 1
  • Da Zhang
    • 1
  1. 1.Department of Oncology, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.School of StatisticsRenmin University of ChinaBeijingChina

Personalised recommendations